Nektar Therapeutics Balance Sheet - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$22.24 $0.07 (0.32%) NKTR stock closing price Jul 21, 2017 (Closing)

The financial analysis of a company involves interpreting the income statement, balance sheet and cash flow statements of the company to draw insights like we've done in our Nektar Therapeutics stock analysis. Balance sheet items like cash at hand, total assets and liabilities helps one analyze a company and summarize the financial performance of the company like we have in our Nektar Therapeutics stock analysis. Quarterly results are typically accompanied with the company releasing financial statements. Nektar Therapeutics revenue was $24.73M and Nektar Therapeutics operating cash flow was $-34.56M for 2017-Q1. The balance sheet shows total liabilities of $483.73M and shareholders equity of $44.74M. View Nektar Therapeutics quarterly results to get the balance sheet details for the latest & last 40 quarters data..

show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4
Marketable Securities335.04M329.46M190.21M219.17M215.77M253.37M249M233.78M171.35M225.45M
Raw Materials1.88M2.05M2.38M2.63M3.05M3.23M1.77M2.39M2.4M2.2M
Work In Progress9.76M7.31M6.69M6.63M7.44M6.08M8.49M6.11M7.66M5.18M
Finished Goods1.36M1.74M1.67M1M0.75M2.02M0.08M1.61M2.44M5.56M
Notes Receivable----------
Other Current Assets7.88M10.36M4M5.42M5.59M9.81M5.21M8.78M6.09M8.81M
Nektar Therapeutics Total Current Assets
Property Plant & Equipment-176.84M---174.04M---164.17M
Accumulated Depreciation-111.24M---102.71M---93.8M
Nektar Therapeutics Net Property Plant & Equipment
Investment & Advances3.49M---------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets0.86M0.51M0.51M0.5M0.68M4.17M13.86M5.76M6.15M6.55M
Nektar Therapeutics Total Assets
Notes Payable----------
Accounts Payable6.95M2.81M7.11M2.32M2.34M2.36M2.27M2.83M5.02M2.7M
Current Portion Long-Term Debt------125M---
Current Portion Capital Leases2.9M2.9M2.37M3.61M4.78M4.75M5.88M5.64M5.41M4.51M
Accrued Expenses29.57M35.14M37.63M36.99M31.06M22.57M43.63M36.4M29.51M26.79M
Income Taxes Payable----------
Other Current Liabilities39.08M31.35M29.17M36.34M27.74M31.55M31.3M36.2M35.49M30.04M
Nektar Therapeutics Total Current Liabilities
Deferred Taxes/Income51.66M51.88M57.08M60.13M59.58M62.42M68.94M73.96M78.41M76.91M
Convertible Debt----------
Long-Term Debt243.9M243.46M243M242.56M242.13M242.11M-125M125M125M
Non-Current Capital Leases1.6M2.22M2.14M2.75M3.32M1.07M1.33M2.88M4.38M4.13M
Other Long-Term Liabilities108.04M110.95M114.4M117.61M121.16M128.77M131.81M138.63M138.65M135.19M
Nektar Therapeutics Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Capital Surplus2.13B2.11B1.91B1.9B1.89B1.88B1.85B1.84B1.83B1.82B
Retained Earnings-2.09B-2.02B-1.98B-1.94B-1.89B-1.87B-1.81B-1.81B-1.75B-1.79B
Treasury Stock----------
Other Liabilities-1.84M-2.36M-1.96M-2.01M-1.83M-2.17M-1.82M-1.49M-1.27M-1.56M
Nektar Therapeutics Shareholders Equity
Nektar Therapeutics Total Liabilities & Shareholders Equity
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Balance sheet for another ticker

Apart from balance sheet items, an investor would do well to keep track of the Nektar Therapeutics stock price by looking at Nektar Therapeutics historical stock prices. One can compare PE with industry average by looking at the Nektar Therapeutics PE ratio chart. The common balance sheet items are:
  • Assets: Anything that the Nektar Therapeutics company owns and is a part of its books. Assets can be of three types: fixed, current and other assets which includes intangibles, advances. Internet companies typically don't have a lot of assets as there is not much investment in say machinery, equipment etc. Nektar Therapeutics had total assets of $528.48M.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Nektar Therapeutics is $483.73M. Shareholders' equity comes under liabilities as it is money the company owes the holders of NKTR stock.

Nektar Therapeutics Balance Sheet - Key Ratios

Current ratio
Debt to Equity ratio
Asset Turnover
receivables turnover
PB ratio (
price to book ratio